Table 1.
Risks of cancer in CKD patients during dialysis.
| Cancer | Study | Number of Participants | Follow-Up (Years) | Age (Years) |
Estimated Risk
(95% CI) |
|---|---|---|---|---|---|
| Overall | Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) [55] | 23,764 | mean 2.7 | 57.5 (43.5–67.6) | SIR 1.45 (1.36–1.54) |
| Pancreatic | A multicenter retrospective cohort study [56] | 6254 | mean 2.4 | 64.0 ± 13.0 | SIR 1.17 (0.31–2.99) |
| Hepatocellular | National Health Institutes Research Database [57] | 92,348 | mean 4.4 | 60.4 ± 14.8 | SIR 1.4 (1.2–1.5) |
| Colorectal | A multicenter retrospective cohort study [56] | 6254 | mean 2.4 | 64.0 ± 13.0 | SIR 1.53 (1.11–2.05) |
| Bladder | a retrospective cohort including United States (USRDS), Europe (EDTA), Australia, and New Zealand (ANZDATA) [58] | 831,804 | mean 2.46 | mean 55.5 | SIR 1.5 (1.4–1.6) |
| Kidney | ANZDATA [55] | 23,764 | mean 2.7 | 57.5 (43.5–67.6) | SIR 5.4 (4.3–6.7) |
| Lung | National Health Institutes Research Database [57] | 92,348 | mean 4.4 | 60.4 ± 14.8 | SIR 0.5 (0.5–0.6) |
| Gastric | A multicenter retrospective cohort study [56] | 6254 | mean 2.4 | 64.0 ± 13.0 | SIR 1.10 (0.47–2.17) |
| Thyroid | A multicenter retrospective cohort study [56] | 6254 | mean 2.4 | 64.0 ± 13.0 | SIR 3.42 (1.25–7.46) |
| Breast | Meta-analysis including 6 studies [52] | 32,057 | 4.4 (3.2–5.4) for dialysis patients | 60 ± 12 for dialysis patients | HR 1.03 (0.50–2.12) |
| Prostate | Meta-analysis including 6 studies [52] | 32,057 | 4.4 (3.2–5.4) for dialysis patients | 60 ± 12 for dialysis patients | HR 0.38 (0.19–0.77) |
| Leukaemia | National Health Institutes Research Database [57] | 92,348 | mean 4.4 | 60.4 ± 14.8 | SIR 0.4 (0.2–0.7) |
| Myeloma | A multicenter retrospective cohort study [56] | 6254 | mean 2.4 | 64.0 ± 13.0 | SIR 1.31 (0.15–4.72) |
Data are presented as values, means ± standard deviation, or medians with interquartile ranges unless otherwise indicated. HR, hazard ratio; SIR, standardized incidence ratio.